Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"Anti-VEGF therapy"”.
-
Role of Macrophages In Adaptive Resistance to Anti-Vegf Therapy
… implementation of therapies targeting the VEGF pathway in cancer has been limited by acquired resistance; yet, the mechanisms by which this occurs is unclear. We investigated the role of macrophages in the development of acquired resistance to anti-VEGF antibody (AVA) therapy.</p> …
-
Anti-VEGF Therapy Modulates Immune Cell Infiltration and Function in Multiple Breast Cancer Models
… angiogenesis is an attractive target for tumor therapy. Many of the current anti-angiogenic therapies target vascular endothelial growth factor-A (VEGF). VEGF binds to and activates two primary VEGF receptors, VEGFR1 and VEGFR2. VEGFR2 is the primary angiogenic receptor, while the function of …
-
Drug Loaded Multifunctional Microparticles for Anti-VEGF Therapy of Exudative Age-related Macular Degeneration
… to AMD. The current intravitreal injection of anti-VEGF (vascular endothelial growth factor) therapies using Avastin or Lucentis has several unmet clinical needs, such as to minimize the frequency of injection, to decrease the systemic side effects, and to evaluate the effect of therapies. We …
-
Role of The Ang-Tie2 Pathway In The Invasive Recurrence of Gbm Following Anti-Vegf Therapy
… of bevacizumab, a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its accelerated approval for the treatment of patients with recurrent glioma. However, despite strong anti-tumor effects, upon treatment with bevacizumab, patients will invariably recur with a …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, however, resistance to such targeted therapies inevitably …
-
The Immunosuppressive Function of VEGF Signaling in the Tumor Microenvironment
… induced by vascular endothelial growth factor-A (VEGF). As a result, anti-VEGF therapy is commonly employed for cancer treatment. However, anti-VEGF therapy generally provides modest efficacy in cancer patients and therapy-induced hypoxia results in a less differentiated mesenchymal-like tumor …
-
Anatomical and functional correlates in ischaemic retinal vein occlusion
… latter group of patients. In fact, intravitreal anti-VEGF, in particular, proved to be as beneficial in ischaemic forms of RVO as in non-ischaemic forms. However, due to the low baseline vision classically found in the ischaemic form, final vision remains lower than in non-iRVO despite …
-
Topical Clear Aqueous Nanomicellar Formulations for Age-Related Macular Degeneration
… treatment available to cure AMD completely. Anti-VEGF therapy is currently considered the treatment of choice. However, it is invasive and does not offer substantial long-term relief to AMD patients. Other treatment options include thermal laser photocoagulation and surgery. None of these …
-
Anti-vascular endothelial growth factor in ophthalmology
… acuity. Based on an intrinsic understanding of VEGF biology and its critical role in ocular pathogenesis, various anti-VEGF strategies tailored specifically to ophthalmologic illnesses were conceived. Pegaptanib, bevacizumab, ranibizumab, aflibercept, and the more recently authorized …
-
Novel nanocarriers to improve drug delivery for age-related macular degeneration
… cure to completely prevent AMD, the invasive anti-VEGF therapy is currently a treatment of choice which does not provide long-term comfort to AMD patients. Other treatment options such as surgery and thermal laser photocoagulation did not appear to be safe for long-term treatment. Hence it is …
-
Mechanistic and therapeutic evaluation of a novel antiantiogenic small molecule
… mediator, vascular endothelial growth factor (VEGF). However, repeated injections of anti-VEGF drugs can cause ocular and systemic side effects, and about 30% of wet AMD patients are non-responsive. There is thus an unmet need to develop VEGF-independent antiangiogenic molecules to complement …